Agios Pharmaceuticals Inc. is tilting at a year-end US approval filing for its first-in-class, oral, targeted inhibitor of the mutant IDH1 enzyme, ivosidenib, for acute myeloid leukemia (AML) as it presented new data at the American Society of Hematology meeting.
Buoyed by the recent early approval of its and partner Celgene Corp.'s oral, targeted inhibitor of isocitrate dehydrogenase-2 (IDH2),...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)